This study examines the relationship between psilocybin reforms and usage patterns of prevalent psychedelics in the United States. Given decriminalization efforts in several cities and legalization in Oregon, the author analyzes drug use panel data from University of Michigan's Monitoring the Future project to assess changes in self-reported use of psilocybin, lysergic acid diethylamide (LSD), and 3,4-methylenedioxymethamphetamine (MDMA, commonly referred to as Molly or Ecstasy). The findings reveal a substitution pattern from LSD and MDMA to psilocybin associated with psilocybin reforms. Given the potential therapeutic benefits of psilocybin and its lower associated risks than LSD and MDMA, the findings suggest a possible public health benefit associated with psilocybin reforms. Moreover, with the increased interest from venture capitalists in the psilocybin-related drug market, this study discusses important topics such as consumer safety and advises caution.
BhaveAshutosh (2024), “Magic of the Mushrooms: Effects of Psilocybin Decriminalization,” Journal of Psychoactive Drugs, 57 (4), 421–30.
2.
BonomoYvonneNormanAmandaBiondoSamBrunoRaimondoDaglishMarkDaweSharonEgerton-WarburtonDianaKarroJonathanKimCharles, et al. (2019), “The Australian Drug Harms Ranking Study,” Journal of Psychopharmacology, 33 (7), 759–68.
3.
Carhart-HarrisRobin L.BolstridgeMarkDayCamilla M.J.RuckerJamesWattsRosalindErritzoeDavid E.KaelenMendelGiribaldiBrunaBloomfieldMichael, et al. (2018), “Psilocybin with Psychological Support for Treatment-Resistant Depression: Six-Month Follow-Up,” Psychopharmacology, 235 (2), 399–408.
4.
Carhart-HarrisRobin L.BolstridgeMarkRuckerJamesDayCamilla M.J.ErritzoeDavidKaelenMendelBloomfieldMichaelRickardJames A.ForbesBen, et al. (2016), “Psilocybin with Psychological Support for Treatment-Resistant Depression: An Open-Label Feasibility Study,” Lancet Psychiatry, 3 (7), 619–27.
5.
Carhart-HarrisRobinGiribaldiBrunaWattsRosalindBaker-JonesMichelleMurphy-BeinerAshleighMurphyRobertaMartellJonnyBlemingsAllanErritzoeDavidNuttDavid J. (2021), “Trial of Psilocybin Versus Escitalopram for Depression,” New England Journal of Medicine, 384 (15), 1402–11.
6.
Carhart-HarrisRobin L.NuttDavid John (2013), “Experienced Drug Users Assess the Relative Harms and Benefits of Drugs: A Web-Based Survey,” Journal of Psychoactive Drugs, 45 (4), 322–28.
7.
CrossinRoseClelandLanaWilkinsChrisRychertMartaAdamsonSimonPotikiTuariPomerleauAdam C.MacDonaldBlairFaletanoaiDwaineHuttonFionaNollerGeoffLambieIanSheridanJane L.GeorgeJasonMercierKaliMaynardKristenLeonardLouiseWalshPatriciaPontonRhysBagshawSue, et al. (2023), “The New Zealand Drug Harms Ranking Study: A Multi-Criteria Decision Analysis,” Journal of Psychopharmacology, 37 (9), 891–903.
8.
FuentesJuan JoséFonsecaFrancinaElicesMatildeFarréMagíTorrensMarta (2023), “Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials,” Frontiers in Psychiatry, 10, 494327.
GriffithsRoland R.JohnsonMatthew W.CarducciMichael A.UmbrichtAnnieRichardsWilliam A.RichardsBrian D.CosimanoMary P.KlinedinstMargaret A. (2016), “Psilocybin Produces Substantial and Sustained Decreases in Depression and Anxiety in Patients with Life-Threatening Cancer: A Randomized Double-Blind Trial,” Journal of Psychopharmacology, 30 (12), 1181–97.
13.
GrobCharles S.DanforthAlicia L.ChopraGurpreet S.HagertyMarycieMcKayCharles R.HalberstadtAdam L.GreerGeorge R. (2011), “Pilot Study of Psilocybin Treatment for Anxiety in Patients with Advanced-Stage Cancer,” Archives of General Psychiatry, 68 (1), 71–78.
JohnsonMatthew W.GriffithsRoland R.HendricksPeter S.HenningfieldJack E. (2018), “The Abuse Potential of Medical Psilocybin According to the 8 Factors of the Controlled Substances Act,” Neuropharmacology, 142, 143–66.
KeesJeremyFitzgeraldPaulaDorseyJoshua D.HillRonald Paul (2020), “Evidence-Based Cannabis Policy: A Framework to Guide Marketing and Public Policy Research,” Journal of Public Policy & Marketing, 39 (1), 76–92.
18.
KellyKathleenBerryChristopherComelloMaria Leonora G.RayHeather Bowen (2021), “The Regulatory and Marketing Environment Surrounding the Legalization of Retail Marijuana and the Impact on Youth,” Journal of Public Policy & Marketing, 40 (1), 62–82.
19.
LeonardJames B.AndersonBruceKlein-SchwartzWendy (2018), “Does Getting High Hurt? Characterization of Cases of LSD and Psilocybin-Containing Mushroom Exposures to National Poison Centers Between 2000 and 2016,” Journal of Psychopharmacology, 32 (12), 1286–94.
MacLeanKatherine A.JohnsonMatthew W.GriffithsRoland R. (2011), “Mystical Experiences Occasioned by the Hallucinogen Psilocybin Lead to Increases in the Personality Domain of Openness,” Journal of Psychopharmacology, 25 (11), 1453–61.
MendeMartinUbalValentina O.CozacMarinaVallenBethBerryChristopher (2024), “Fighting Infodemics: Labels as Antidotes to Mis- and Disinformation?!” Journal of Public Policy & Marketing, 43 (1), 31–52.
25.
MitchellJennifer M.BogenschutzMichaelLiliensteinAliaHarrisonCharlotteKleimanSarahParker-GuilbertKellyOt’alora G.MarcelaGarasWaelPaleosCaseyGormanIngmarNicholasChristopherMithoeferMichaelCarlinShannonPoulterBruceMithoeferAnnQuevedoSylvestreWellsGregoryKlaireSukhpreet S.van der KolkBesselTzarfatyKeren, et al. (2023), “MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study,” Focus, 21 (3), 315–28.
26.
MorenoFrancisco A.WiegandChristopher B.TaitanoE. KeolaniDelgadoPedro L. (2006), “Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients with Obsessive-Compulsive Disorder,” Journal of Clinical Psychiatry, 67 (11), 1735–40.
PatrickMegan E.MiechRichard A.JohnstonLloyd D.O’MalleyPatrick M. (2024), “Monitoring the Future Panel Study Annual Report: National Data on Substance Use Among Adults Ages 19 to 65, 1976–2023,” Monitoring the Future, Institute for Social Research, University of Michigan, https://monitoringthefuture.org/wp-content/uploads/2024/07/mtfpanel2024.pdf.
RosemanLeorNuttDavid J.Carhart-HarrisRobin L. (2018), “Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression,” Frontiers in Pharmacology, 8, 309463.
36.
RossStephenBossisAnthonyGussJeffreyAgin-LiebesGabrielleMaloneTaraCohenBarryMennengaSarah E.BelserAlexanderKalliontziKrystallia, et al. (2016), “Rapid and Sustained Symptom Reduction Following Psilocybin Treatment for Anxiety and Depression in Patients with Life-Threatening Cancer: A Randomized Controlled Trial,” Journal of Psychopharmacology, 30 (12), 1165–80.
SarkeesMatthew E.FitzgeraldM. PaulaLambertonCait (2022), “Pharmaceuticals, Marketing, and Society: A New Center of Gravity for Critical Research and Policy,” Journal of Public Policy & Marketing, 41 (4), 299–303.
39.
SiegelJoshua S.DailyJames E.PerryDemetrius A.NicolGinger E. (2023), “Psychedelic Drug Legislative Reform and Legalization in the US,” JAMA Psychiatry, 80 (1), 77–83.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
